万邦德：在研小分子多肽新药已取得良好前期数据，有计划推进临床转化

Core Viewpoint - The company Wanbangde (002082) is developing a small molecule peptide drug that shows promising preclinical data for obesity and diabetes indications, with plans to advance to clinical trials [1] Group 1: Drug Development - The small molecule peptide drug is currently in the preclinical stage and has shown good preliminary data [1] - The drug targets different mechanisms compared to GLP-1 class drugs like Semaglutide [1] - Preclinical data indicates that the drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves various metabolic indicators [1] Group 2: Comparative Efficacy - In studies involving diabetic obese mice, the weight loss efficiency of the new drug significantly outperformed that of Semaglutide [1]